Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.

Verve is developing therapies targeting genes that regulate cholesterol in the liver.

(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)